M. Streetly

Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option

I. Lazana, A. Pagliuca, K. Bramham, 2022, Bone Marrow Transplantation.

Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation

G. Mufti, M. Bornhäuser, A. Mohamedali, 2018, Leukemia.

Second autologous transplant with cyclosporin/interferon α-induced graft versus host disease for patients who have failed first-line consolidation

M. Kazmi, C. Hoyle, D. Radia, 2004, Bone Marrow Transplantation.

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.

A. Dalgleish, P. Fields, R. Knight, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)

C. Crawley, J. Cavenagh, G. Cook, 2017 .

Machine learning from the CARDAMON trial identifies a carfilzomib-specific mutational response signature

M. Chapman, J. Cavenagh, R. Benjamin, 2023, medRxiv.